JP Morgan Chase
PLRX icon

JP Morgan Chase’s Pliant Therapeutics PLRX Stock Holding History

JP Morgan Chase’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-200,200
Closed -$5.33M – 7243
2023
Q1 		$5.33M Buy
+200,200
New +$5.7M ﹤0.01% 2767

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

JP Morgan Chase's PLRX Position: Q1 2026 in Review

JP Morgan Chase reduced its Pliant Therapeutics (PLRX) stake by 29% in Q1 2026, selling an estimated $443K and leaving 861,823 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #4608.

JP Morgan Chase first reported a position in PLRX in Q3 2020 and has held it in 23 quarters since. The position peaked at $3.15M in Q3 2025. 91 funds tracked by Wall St. Rank hold PLRX as of Q1 2026.

  • JP Morgan Chase held 861,823 shares of Pliant Therapeutics worth $1.01M as of Q1 2026.
  • JP Morgan Chase sold 351,052 Pliant Therapeutics shares in Q1 2026, an estimated $443K.
  • Pliant Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4608 holding.
  • JP Morgan Chase first reported a position in Pliant Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • JP Morgan Chase's Pliant Therapeutics position peaked at $3.15M in Q3 2025.
  • 91 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.